Abstract
The amyloid beta (Abeta) peptide is responsible for toxic amyloid plaque formation and is central to the aetiology of Alzheimer’s disease (AD). It is generated by proteolytic processing of the amyloid precursor protein (APP) by beta-secretase (BACE-1) and gamma-secretase. Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach to the treatment of Alzheimer’s disease. This paper reports on improved microtiter plate-based fluorescence and colorimetric assays for the high-throughput screening (HTS) of BACE-1 inhibitors achieved by employing, for the first time, casein fluorescein isothiocyanate (casein-FITC) and N-α-benzoyl-D,L-arginine p-nitroanilide (BAPNA) as substrates, since they are known to be readily available and convenient substrates for proteases. The methods are based on the fluorescence enhancement following casein-FITC proteolysis and the visible absorbance of the p-nitroaniline (pNA) produced by BAPNA hydrolysis, with both reactions catalysed by BACE-1. Casein-FITC is a high-affinity substrate (K m = 110 nM) for BACE-1, more so than the Swedish (SW) type peptide (a peptide containing the Swedish mutant of APP, a familiar mutation that enhances Abeta production). BACE-1 catalysis of casein-FITC proteolysis exhibited Michaelis–Menten kinetic. Therefore, it was found that BACE-1 was saturable with casein-FITC that was processed in a time- and pH-dependent manner with greater catalytic efficiency than observed for the SW peptide. The enantioselective hydrolysis of L-BAPNA by BACE-1 was observed. l-BAPNA was hydrolysed ten times more efficiently by BACE-1 than the WT (wild-type peptide). The novel methods were validated using a FRET assay as an independent reference method. Therefore, in order to select new leads endowed with multifunctional activities, drugs for Alzheimer’s disease (AD)—potent acetylcholinesterase (AChE) inhibitors—were tested for BACE-1 inhibition using the proposed validated assays. Among these, donepezil, besides being an acetylcholinesterase inhibitor, was also found to be a BACE-1 inhibitor that displayed submicromolar potency (170 nM).
Similar content being viewed by others
References
Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, Van Gool WA, Hoozemans JJ (2006) J Neural Transm 113:1685–1695
Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002) Biochem Soc Trans 30:552–557
Vassar R (2004) J Mol Neurosci 23:105–114
Evin G, Zhu A, Holsinger RM, Masters CL, Li QX (2003) J Neurosci Res 74:386–392
Evin G, Sernee MF, Masters CL (2006) CNS Drugs 20:351–372
Durham TB, Shepherd TA (2006) Curr Opin Drug Discov Dev 9:776–791
Park H, Lee S (2003) J Am Chem Soc 125:16416–16422
Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB (2007) J Neurochem 100:802–809
Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J (2000) Proc Natl Acad Sci USA 97:1456–1460
Ghosh AK, Shin D, Downs D, Koelsch G, Lin X, Ermolieff J, Tang J (2000) J Am Chem Soc 122:3522–3523
Lamar J, Hu J, Bueno AB, Yang H-C, Guo D, Copp JD, McGee J, Gitter B, Timm D, May P, Mccarthy J, Chen S-H (2004) Bioorg Med Chem Lett 14:239–243
Kennedy ME, Wang W, Song L, Lee J, Zhang L, Wong G, Wang L, Parker E (2003) Anal Biochem 319:49–55
Pietrak BL, Crouthamel MC, Tugusheva K, Lineberger JE, Xu M, DiMuzio JM, Steele T, Espeseth AS, Stachel SJ, Coburn CA, Graham SL, Vacca JP, Shi XP, Simon AJ, Hazuda DJ, Lai MT (2005) Anal Biochem 342:144–151
Bolognesi ML, Minarini A, Tumiatti V, Melchiorre C (2006) Mini Rev Med Chem 6:1269–1274
Bolognesi ML, Andrisano V, Bartolini M, Banzi R, Melchiorre C (2005) J Med Chem 48:24–27
Melchiorre C, Andrisano V, Bolognesi ML, Budriesi R, Cavalli A, Cavrini V, Rosini M, Tumiatti V, Recanatini M (1998) J Med Chem 41:4186–4189
Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, Bartolini M, Andrisano V, Valenti P, Recanatini M (2003) J Med Chem 46:2279–2282
Rosini M, Andrisano V, Bartolini M, Bolognesi ML, Hrelia P, Minarini A, Tarozzi A, Melchiorre C (2005) J Med Chem 48:360–363
Twining SS (1984) Anal Biochem 143:30–34
Veloso ACA, Teixeira N, Ferreira I (2002) J Chromatogr A 967:209–218
Garino C, Pietrancosta N, Moret V, Rolland A, Quelever G, Kraus JL (2006) Bioorg Med Chem Lett 16:1995–1999
Erlanger BF, Kokowsky N, Cohen W (1961) Arch Biochem Biophys 95:271–278
Sinha S, Anderson JP, Barbour R, et al. (1999) Nature 402:537–540
Acknowledgements
We thank C.I.R.B. for the use of the Fluoroskan Ascent multiwell spectrofluorometer. MIUR (Rome, Italy) is gratefully acknowledged for financial support (FIRB and PRIN funds).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mancini, F., Naldi, M., Cavrini, V. et al. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Anal Bioanal Chem 388, 1175–1183 (2007). https://doi.org/10.1007/s00216-007-1356-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-007-1356-2